Her2V655 genotype and breast cancer progression in Korean women

Pathology International

Volumn 55, Issue 2, 2005, Pages 48-52

  An, Hee Jung ^a   Kim, Nam Keun ^a   Oh, Doyeun ^a   Kim, Sae Hyun ^a   Park, Min Jung ^a   Jung, Moon Young ^a   Kang, Haeyoun ^a   Kim, Seung Gi ^a   Lee, Kyung Po ^a   Lee, Kyung Sik ^a  

^a CHA University   (South Korea)

Author keywords

Breast cancer; Codon 655; Her2 polymorphism; Korean women

Indexed keywords

EPIDERMAL GROWTH FACTOR RECEPTOR 2; GENOMIC DNA; ONCOPROTEIN; VALINE;

ADULT; AGED; ALLELE; ARTICLE; BREAST CANCER; CANCER RISK; CODON; CONTROLLED STUDY; ETHNIC GROUP; FEMALE; GENE OVEREXPRESSION; GENETIC POLYMORPHISM; HUMAN; IMMUNOHISTOCHEMISTRY; KOREA; MAJOR CLINICAL STUDY; NUCLEOTIDE SEQUENCE; ONCOGENE NEU; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTO ONCOGENE; BREAST TUMOR; DISEASE COURSE; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; METABOLISM; MIDDLE AGED; PAGET NIPPLE DISEASE; PATHOLOGY; RISK; RISK FACTOR;

ADULT; AGED; BREAST NEOPLASMS; CARCINOMA, DUCTAL, BREAST; CARCINOMA, INTRADUCTAL, NONINFILTRATING; DISEASE PROGRESSION; FEMALE; GENES, ERBB-2; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; IMMUNOHISTOCHEMISTRY; KOREA; MIDDLE AGED; ODDS RATIO; ONCOGENE PROTEINS V-ERBB; POLYMORPHISM, GENETIC; RISK FACTORS; VALINE;

EID: 20044384877     PISSN: 13205463     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1440-1827.2005.01789.x     Document Type: Article

References (22)

1. Slamon DJ, Clark GM, Wong SG, Levin WJ, Ullrich A, McGuire WL. Human breast cancer: correlation of relapse and survival with amplification of the HER2/neu oncogene. Science 1987; 235: 177-82.
2. Pauletti G, Godolphin W, Press MF, Slamon DJ. Detection and quantitation of HER-2/neu gene amplification in human breast cancer archival material using fluorescence in situ hybridization. Oncogene 1996; 13: 63-72.
3. Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer 1998; 34: 791-808.
4. Venter DJ, Tuzi NL, Kumar S, Gullick WJ. Overexpression of the c-erbB-2 oncoprotein in human breast carcinomas: immunohistological assessment correlates with gene amplification. Lancet 1987; 11: 69-71.
5. Berger MS, Locher GW, Saurer S et al. Correlation of c-erbB-2 gene amplification and protein expression in human breast carcinoma with nodal status and nuclear grading. Cancer Res 1988; 48: 1238-43.
6. Lemoine NR, Staddon S, Dickson C, Barnes DM, Gullick WJ. Absence of activating trasmembrane mutations in the c-erbB2 proto-oncogene in human breast cancer. Oncogene 1990; 5: 237-9.
7. Bargmann CI, Hung MC, Weinberg RA. Multiple independent activations of the neu oncogene by a point mutation altering the transmembrane domain of p185. Cell 1986; 45: 649-57.
8. Xie D, Shu WO, Deng Z et al. Population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2000; 92: 412-17.
9. Kuraoka K, Matsumura S, Hamai Y et al. A single nucleotide polymorphism in the transmembrane domain coding region of HER-2 is associated with development and malignant phenotype of gastric cancer. Int J Cancer 2003; 20: 593-6.
10. Wang L, Habuchi T, Takahashi T et al. No association between Her-2 gene polymorphism at codon 655 and a risk of bladder cancer. Int J Cancer 2002; 97: 787-90.
11. Baxter SW, Campbell IG. Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2001; 93: 557-8.
12. Keshava C, McCanlies EC, Keshava N, Wolff MS, Weston A. Distribution of HER2(V655) genotypes in breast cancer cases and controls in the United States. Cancer Lett 2001; 173: 37-41.
13. Millikan R, Eaton A, Worley K et al. HER2 codon 655 polymorphism and risk of breast cancer in African Americans and whites. Breast Cancer Res Treat 2003; 79: 355-64.
14. Ameyaw MM, Tayeb M, Thornton N et al. Ethnic variation in the HER-2 codon 655 genetic polymorphism previously associated with breast cancer. J Hum Genet 2002; 47: 172-5.
15. American Joint Committee on Cancer. Breast. In: Greene FL, ed. AJCC Cancer Staging Manual, 5th edn. Philadelphia: Lipincott-Raven Publishers, 1997; 171-80.
16. Zhang W, Kataoka N, Xiw D. Re: population-based, case-control study of HER2 genetic polymorphism and breast cancer risk. J Natl Cancer Inst 2001; 93: 558-9.
17. Montgomery KG, Gertig DM, Baxter SW et al. The Her2 1655Vpolymorphism and risk of breast cancer in women < age 40 years. Cancer Epidemiol Biomarkers Prey 2003; 12: 1109-11.
18. Papewalis J, Nikitin AYu, Rajewsky MF. G to A polymorphism at amino acid codon 655 of the human etbB-2/Her2 gene. Nucleic Acids Res 1991; 19: 5452.
19. Bargamann CI, Weinberg RA. Oncogenic activation of the neuencoded receptor protein by point mutation and deletion. EMBO J 1988; 7: 2043-52.
20. Segatto O, King CR, Pierce JH et al. Different structural alterations upregulate in vitro tyrosine kinase activity and transforming potency of the erbB-2 gene. Mol Cell Biol 1988; 8: 5570-74.
21. 2H NMR in fluid phospholipid bilayers. Biochemistry 2000; 39; 6572-80.
22. Fleishman SJ, Schlessinger J, Ben-Tal N. A putative molecular-activation switch in the transmembrane domain of erbB2. Proc Natl Acad Sci USA 2002; 99: 15 937-40.